Evaluation of small dose aripiprazole for the treatment of alcohol use disorders: a randomized, double-blind, placebo-controlled study.

Phase 2

• Conditions: Alcohol use disorders

• Registration Number: JPRN-UMIN000011707
• Lead Sponsor: Department of Psychiatry, Chiba University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-09-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

1. Comatose state 2. Influence of the central nerve inhibitor such as a barbituric acid derivative, the anesthetic 3. Current use of any other dopamine D2 agonist or antagonist 4. Current use of any other antialcoholic drug 5. Other current drug abuse or dependence 6. Use of epinephrine 7. Allergy or hypersensitivity to aripiprazole 8. Woman during pregnancy or shortly after childbirth 9. High suicidal risk 10. Uncontrollable diabetic 11. Decreased liver function (aminotransferase greater than 5 times normal) or cirrhosis more than Child C 12. Current major psychiatric disorder 13. Current dementia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of change of carbohydrate-deficient transferrin (%CDT) in the 4week and the 12 week

Secondary Outcome Measures

Name	Time	Method
1. Days abstinent from drinking 2. Drinks per day 3. Drinks per drinking day 4. The obsessive-compulsive drinking scale(OCDS) 5. Electroencephalography(Voluntary participation)